Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Board Changes

16 Sep 2009 07:01

RNS Number : 1250Z
TyraTech, Inc.
16 September 2009
Β 

ο»Ώ

For immediate release

16 SeptemberΒ 2009

TYRATECH, INC.

("TyraTech" or "the Company")

Board Changes

TyraTech, Inc. (AIM: TYR), aΒ leading independent novel eco-technology company for human, animal and environmental health, is pleased to announce thatΒ Patrick ReganΒ will join the BoardΒ as aΒ Non-Executive Director andΒ thatΒ DavidΒ PaulΒ SzostakΒ will step down from the Board asΒ aΒ Non-ExecutiveΒ Director.Β MrΒ Szostak joined the Board in April 2008Β to represent XL TechGroupΒ andΒ willΒ nowΒ step down from the Board.Β Both changes take placeΒ with immediate effect.Β 

Mr ReganΒ thirty sevenΒ joins the Board as a representative of theΒ Laurus-ValensΒ Group, the parent Group ofΒ PetroTech Holdings Corporation,Β which has a 45.69% shareholding in TyraTech.Β HeΒ bringsΒ to the Board overΒ sixteenΒ years of financial analysis,Β corporateΒ management,Β investment banking and venture capitalΒ experience gained in theΒ US.Β Mr ReganΒ hasΒ beenΒ a senior managing director for Laurus Capital Management LLC since 2001 andΒ hasΒ also servedΒ the same role at Valens Capital Management LLC since its establishment in 2007.Β 

In addition to hisΒ fund management experience atΒ Laurus-Valens, heΒ hasΒ spent four years as a financial analyst at Geller & Company, a financial services accounting firm,Β primarily providing CFO functions to private companies and financial planning for high net worth individuals. At Geller,Β he was involved in private placement financing, management consulting and general corporate finance functions.Β Between 1999 and 2001,Β PatrickΒ Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm.

Mr Regan has a Bachelor of Science in Business and Economics fromΒ LehighΒ UniversityΒ and an MBA fromΒ FordhamΒ University.Β 

Mr. ReganΒ has no otherΒ previousΒ orΒ current Directorships.Β 

There are no further details required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules.

Commenting on the board changesΒ Geoffrey Vernon, Chairman of TyraTech,Β said:

"I am delighted to welcomeΒ Patrick ReganΒ to the Board as he brings a wealth of experience of matters across a range of different areas important toΒ TyraTech.Β His understanding of the financial dynamics of small cap companiesΒ and hisΒ investment banking and venture capitalΒ experienceΒ will be beneficial to the Group."

"I would like to express my sincere gratitude to DavidΒ for his experience and expertise throughout his timeΒ at TyraTechΒ and wish him well for the future. His contribution has beenΒ highlyΒ valuable."

For further information please contact:

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7723

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker/Clare Terlouw +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Mary-Janeί›Β ElliottΒ / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

www.buchanan.uk.com

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech,Β which already has productsΒ on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech'sΒ Nature's Technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, andΒ for consumer and professional pest control. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visitΒ www.tyratech.comΒ 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAMGGMLMKGGLZZ
Date   Source Headline
24th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20157:00 amRNSMigration of shares
6th Aug 20157:00 amRNSMigration of Shares
30th Jul 20154:38 pmRNSResult of AGM
3rd Jul 20155:04 pmRNSMigration of Shares
22nd Jun 20157:00 amRNSFinal Results
10th Jun 20152:22 pmRNSMigration of Shares
26th May 20157:01 amRNSSmartPak launches OutSmart insect repellent
21st May 20155:45 pmRNSMigration of Shares
22nd Apr 20157:00 amRNSDirector's Dealings
20th Apr 20157:00 amRNSEnvance LLC amended: Sharpened strategic focus
9th Apr 20151:14 pmRNSMigration of Shares
8th Apr 20157:00 amRNSListing with Walgreens in the USA
27th Mar 20159:41 amRNSMigration of Shares and Exercise of SARs
25th Mar 20157:00 amRNSVamousse now distributed by CVS in the USA
3rd Mar 20157:00 amRNSVamousse now listed by the top 3 distributors, USA
25th Feb 20157:00 amRNSLloyds and Day Lewis Pharmacy listings
16th Feb 20155:01 pmRNSDirector's Dealings
2nd Feb 20157:00 amRNSVamousse at Walmart and Cardinal Health USA
26th Jan 20157:00 amRNSInnovators and Investors Forum, London
15th Jan 20157:00 amRNSAppointment of Chief Financial Officer & Treasurer
2nd Dec 20147:00 amRNSTrading Update
1st Oct 20147:00 amRNSExercise of Warrants
29th Sep 20147:00 amRNSInterim Results
27th Aug 20147:00 amRNSVamousse products coming to Sainsbury's and Tesco
8th Aug 201410:30 amRNSHolding(s) in Company
5th Aug 201410:29 amRNSHolding(s) in Company
1st Aug 20145:49 pmRNSHolding(s) in Company
1st Aug 20142:40 pmRNSHolding(s) in Company
28th Jul 20145:35 pmRNSResult of Special Meeting & Director Shareholdings
16th Jul 20147:00 amRNSResult of AGM
16th Jul 20147:00 amRNSPlacing to raise £3.5m and launch of UK Vamousse
26th Jun 20147:00 amRNSFinal Results
22nd May 20144:02 pmRNSMigration of Shares
19th May 20146:15 pmRNSMigration of Shares
19th May 20147:00 amRNSVamousse product line available online across USA
30th Apr 20147:00 amRNSNatunex product launched across USA
24th Apr 20147:00 amRNSUSA Pest Control Patents Secured
8th Apr 20146:10 pmRNSDirector's Dealings
7th Apr 20144:41 pmRNSDirector's Dealings
1st Apr 20147:00 amRNSVamousse at over 4,000 Walmart Stores in USA
7th Mar 20147:00 amRNSMigration of Shares
6th Mar 201411:48 amRNSHolding(s) in Company
6th Mar 20147:00 amRNSAward of Share Options
24th Feb 20147:00 amRNSProposed Migration of Shares
18th Feb 20143:38 pmRNSResult of Special Meeting
13th Feb 20149:47 amRNSHolding(s) in Company
31st Jan 20144:26 pmRNSProposed Placing
23rd Jan 20145:58 pmRNSHolding(s) in Company
20th Jan 20147:00 amRNSHead-Lice Preventative Shampoo Coming to US Market

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.